Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Revenue decreased by JPY135mn to JPY21.8bn due to smaller milestone payments, partially offset by Quviviq sales.</li><li>R&D expenses rose 31.5% YoY to JPY11.2bn, driven by increased investment and a weaker yen, mainly in the UK.</li><li>Core operating loss was JPY986mn, compared to a JPY4.4bn profit in cumulative Q3 FY12/24, reflecting non-cash expenses.</li></ul>

Revenue decreased by JPY135mn to JPY21.8bn due to smaller milestone payments, partially offset by Quviviq sales.R&D expenses rose 31.5% YoY to JPY11.2bn, driven by increased investment and a weaker yen, mainly in the UK.Core operating loss was JPY986mn, compared to a JPY4.4bn profit in cumulative Q3 FY12/24, reflecting non-cash expenses.

Sosei Group (4565 JP): Q3 FY12/25 flash update

<ul><li>Revenue increased 44.1% YoY to JPY6.6bn, driven by Quviviq® revenue and milestone payments in Q1 FY12/25.</li><li>R&D expenses rose 20.4% YoY to JPY3.8bn, influenced by increased R&D investment and a weaker yen.</li><li>Core operating loss was JPY625mn, improved from JPY931mn in Q1 FY12/24, reflecting reduced non-cash and one-time expenses.</li></ul>

Revenue increased 44.1% YoY to JPY6.6bn, driven by Quviviq® revenue and milestone payments in Q1 FY12/25.R&D expenses rose 20.4% YoY to JPY3.8bn, influenced by increased R&D investment and a weaker yen.Core operating loss was JPY625mn, improved from JPY931mn in Q1 FY12/24, reflecting reduced non-cash and one-time expenses.

Sosei Group (4565 JP): Q1 FY12/25 flash update

Japan

Sosei Group Corporation is a holding company which was established through reorganization.  The Group companies are biopharmaceutical companies specializing in drug development.  Sosei Group enters into license agreements primarily with US, EU, and Japanese companies to market the licensed drugs in Japan and find alternative usage on such drugs.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sosei Group (4565 JP)